Cargando…
The Use of Epidermal Growth Factor Receptor Monoclonal Antibodies in Squamous Cell Carcinoma of the Head and Neck
Targeting of the EGF receptor (EGFR) has become a standard of care in several tumor types. In squamous cell carcinoma of the head and neck, monoclonal antibodies directed against EGFR have become a regular component of therapy for curative as well as palliative treatment strategies. These agents hav...
Autores principales: | Russell, Jeffery S., Colevas, A. Dimitrios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488396/ https://www.ncbi.nlm.nih.gov/pubmed/23150825 http://dx.doi.org/10.1155/2012/761518 |
Ejemplares similares
-
Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck
por: Iberri, David J., et al.
Publicado: (2016) -
Honokiol inhibits the growth of head and neck squamous cell carcinoma by targeting epidermal growth factor receptor
por: Singh, Tripti, et al.
Publicado: (2015) -
Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts.
por: Stanton, P., et al.
Publicado: (1994) -
Mtss1 regulates epidermal growth factor signaling in head and neck squamous carcinoma cells
por: Dawson, John C., et al.
Publicado: (2011) -
Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status
por: Hofman, P, et al.
Publicado: (2008)